ACTU vs MRK · $49.0M cap vs P/E 33, rev $16.61B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
ACTU does not have a complete income-statement cache yet.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
ACTU currently screens at market cap $49.0M. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the ACTU and MRK stock pages for the full models.
Not investment advice.